FalconM89

CURA LONG for 2021-2022

Long
CSE:CURA   None
Curaleaf reminds me of Canopy when I bought them at $2.15 CAD after Trudeau was elected. No one knew Canopy but two years from that point everyone from grandmas to hedge fund investors were talking about them. Curaleaf is the best play right now for US legislative plays and I don't know anyone who is talking about them. The news cycle is starting to make its rounds in the trading world about a potential parabolic set up. I think this will happen. When it happens no person can honestly say, although if I were to guess it would be on the cusp of the legislation being actually within 2 years, but most likely much earlier.

In the meantime, I think this is a good entry for a base position. Monthly volume and momentum has been very strong and supportive of the price increases. The recent offering was slightly below the current price at $16.70. Price targets have $24 in their sights, but I know from the Canadian MJ sector, those targets can get lifted very fast as new investors and traders flood in. Asides US legislation we also have Mexico legalization to put MJ more firmly on the investment radar and this will be coming up early into the year. It may catch the bears off guard and give us fuel to a new higher base in the high $20s. When the price reaches high $20 it will be sure to attract more bears and that is when things will get interesting and very volatile.

This is a highly speculative play that runs contrary to fundamentals, so I wouldn't suggest throwing in your life savings. Also, parabolic moves tend to happen when the situation looks most bearish, so to get to the point of a parabolic move you need to be able to hold strong - over extending yourself by risking too much money makes that very difficult. I have just under 3,000 shares and I am content to leave that in the market over the next two years. Good luck.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.